Alternative Energy Sources for Surgical Treatment of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery: Microwave Ablation vs Cryoablation by Kim, Joon Bum et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Alternative Energy Sources for Surgical Treatment of Atrial 
Fibrillation in Patients Undergoing Mitral Valve Surgery: 
Microwave Ablation vs Cryoablation
The study aim was to compare maze outcomes using microwave ablation or cryoablation 
in patients with mitral disease and atrial fibrillation (AF). Between 1999 and 2005, 340 
patients underwent mitral valve surgery and concomitant maze procedure involving either 
microwave ablation (n=96, MW group) or cryoablation (n=244, Cryo group). Mean age at 
operation was 50.0±12.5 yr. Follow-up period was 46.1±28.2 months. The Cryo group 
showed a longer aortic clamping time than the MW group (P=0.005). There were no 
differences in operative mortality and morbidity rates. The unadjusted 5-yr AF free rate was 
61.3±1.2% in the MW group and 79.9±3.2% in the Cryo group (P=0.089). After 
adjustment, the MW group only showed a tendency toward more frequent AF recurrence 
than the Cryo group (Hazard ration 1.66, 95% confidence interval 0.89 to 3.07). 
Multivariate analysis revealed that older patient age (P<0.001) and greater left atrial size 
(P<0.001) were independent risk factors for AF recurrence. Although the use of microwave 
ablation results in shorter aortic clamping time, it has a tendency toward more frequent 
late AF recurrence than with cryoablation.
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
The maze procedure described by Cox (1, 2) is an accepted, ef-
fective therapeutic option for patients with atrial fibrillation (AF). 
In recent years, the conventional cut-and-sew Cox Maze proce-
dure has been replaced by other procedures using alternative 
energy sources such as radiofrequency, microwaves, ultrasound, 
laser, and cryothermia to rapidly produce maze lesion sets with 
minimal risk of bleeding (3-5). Several studies have investigated 
the effectiveness of these energy sources and have shown vary-
ing results in terms of restoration of sinus rhythm (6). 
  However, previous comparative analyses of clinical outcomes 
according to different energy sources have had limitations, in-
cluding short follow-up durations (<1 yr) and small patient pop-
ulations (6-9). Furthermore, different definitions of procedural 
success may have contributed to the difficulties in interpreting 
or comparing the reported outcomes.
  We therefore compared the long-term clinical outcomes of 
maze procedures using microwave ablation or cryoablation in 
patients with mitral disease and AF. In reporting the rhythm 
outcomes, we followed the consensus of reporting standards 
made by the Heart Rhythm Society Task Force on Catheter and 
Surgical Ablation of AF (10).
MATERIALS AND METHODS
Patients 
Between January 1999 and January 2005, 340 consecutive pa-
tients underwent a mitral valve operation and concomitant maze 
procedure involving microwave ablation (n=96, MW group) or 
cryoablation (n=244, Cryo group) by a single cardiac surgeon in 
Asan Medical Center, Seoul, Korea. This patient population in-
cludes 158 patients (46.5%) who were analyzed in a previous 
report regarding the influence of mitral valve function on AF 
recurrence after mitral repair and maze procedure (11). Further 
follow-up data from the patients included in the previous study, 
and the addition of data from mitral replacement patients formed 
the subject of the present study to focus on the comparison be-
tween cryoablation and microwave ablation. 
Surgical techniques 
Myocardial protection was achieved with antegrade and retro-
grade tepid blood cardioplegia. After aortic cross-clamping, mi-
tral valve exposure was obtained by a left atrial (LA) incision. A 
modified version of the Cox Maze III procedure was performed, 
the details of which have been described previously (12). Cryo-
ablation was applied at –60°C with a 15-degree-angled, 30-mm 
or 70-mm long freeze tip with a diameter of 9 mm (Frigitronics Kim JB, et al.  •   Microwave Ablation vs. Cryoablation for Surgical Treatment of Atrial Fibrillation
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Cardiac Cryosurgical System 200; Frigitronics, Inc, Coopersur-
gical, Shelton, CT, USA). The probe was usually applied for 2 
min. Microwave energy was applied endocardially using FLEX 
4 microwave ablation probes (Afx Inc, Fremont, CA, USA). The 
energy level used was 65 watts and duration of ablation was 2 
min. LA size was reduced by generous resection of redundant 
atrial tissue off the posterior LA wall parallel to the posterior 
mitral annulus. During the study period, the lesion set of abla-
tion procedure was maintained uniformly regardless of energy 
sources used.
Echocardiography and rhythm follow-up 
Preoperative echocardiography (both transthoracic and trans-
esophageal) was performed in all patients (within 2 months  
before surgery). Transthoracic echocardiographic evaluation 
was performed at 3 and 6 months and every year thereafter. All 
patients underwent two-dimensional echocardiography and 
Doppler color-flow imaging using a Hewlett-Packard Sonos 
2500 or 5500 imaging system equipped with a 2.5-MHz trans-
ducer (Hewlett-Packard, Andover, MA, USA). 
  During postoperative hospitalization, each patient’s rhythms 
were assessed daily using standard 12-channel surface electro-
cardiography (EKG). Follow-up EKGs were performed at 3–6- 
month intervals during the first 2 yr and every year thereafter. 
Any AF events during the initial post-ablation blanking period 
of 3 months were defined as “early events.” Failure of the maze 
procedure included any recurrent AF, atrial tachycardia, or atri-
al flutter at least 3 months after stopping amiodarone treatment 
beyond the initial blanking period (“late event”). The results are 
presented in ‘Freedom from AF without antiarrhythmic agent’ 
(10). 
  All data were collected prospectively and stored for later anal-
ysis in a specially designed and regimented database. 
Postoperative management
Indications for amiodarone treatment included: failure of post-
operative sinus conversion, persistent AF, atrial tachycardia, fre-
quent atrial premature beat and recurrent atrial tachyarrhyth-
mia. Amiodarone was commenced at 1,200 mg/day and tapered 
within 1 or 2 weeks. Patients who underwent valve repair or bio-
prosthetic valve implantation were routinely administered an-
ticoagulant therapy with warfarin for 3–6 months postoperative-
ly, with a target international normalized ratio (INR) of 1.5–2.5 
at the discretion of the attending surgeon. Maintenance of anti-
coagulation therapy thereafter was determined according to the 
presence of thromboembolic risks and cardiac rhythm status in 
each patient.
Statistics 
Categorical variables are presented as frequencies and percent-
ages, and were compared using the chi-square test or Fisher’s 
exact test. Continuous variables are expressed as mean±SD or 
medians with ranges, and were compared using the Student’s 
unpaired t-test or the Mann-Whitney U test, as appropriate. Ka-
plan-Meier curves were employed to delineate freedom from 
AF, and log-rank test was used to compare the differences in AF-
free rates between groups.
  To reduce the impact of treatment selection bias and potential 
confounding in an observational study, we performed rigorous 
adjustment for significant differences in patient characteristics 
by using inverse-probability-of-treatment weighting (IPTW) (13, 
14). With that technique, weights for patients receiving micro-
wave ablation were the inverse of (1 minus propensity score), 
and weights for patients receiving cryoablation were the inverse 
of propensity score. The propensity scores were estimated by 
multiple logistic-regression analysis (14). All prespecified covari-
ates were included in full nonparsimonious models for micro-
wave ablation versus cryoablation (Tables 1, 2). The discrimina-
tion and calibration abilities of each propensity score model 
were assessed by C statistics and the Hosmer-Lemeshow test. 
The model was well calibrated (Hosmer-Lemeshow test; P= 
0.866) with reasonable discrimination (C statistic=0.702). 
  For multivariate analyses, the Cox proportional hazards mod-
el was fitted with time to AF recurrence. Variables with a proba-
bility value ≤0.20 in univariate analyses were candidates for the 
Table 1. Preoperative profiles of patients 
Variables Cryo group MW group P value
Number of patients 244 96
Age (yr)   49.7±12.1   50.7±13.5 0.514
Female gender, n (%)    154 (63.1) 54 (56.2) 0.242
Diabetes mellitus, n (%)    16 (6.6) 9 (9.4) 0.364
Hypertension, n (%)    20 (8.2) 6 (6.3) 0.654
History of thromboembolism, n (%)      29 (11.9) 9 (9.4) 0.571
Cardiothoracic ratio, % 60.1±7.2   58.3±11.5 0.158
Previous cardiac surgery, n (%)    20 (8.2) 4 (4.2) 0.243
Causes of MV disease, n (%)
   Rheumatic
   Degenerative
   174 (71.3)
     70 (28.7)
53 (55.2)
43 (44.8)
 0.005*
Mode of MV disease, n (%)
   Predominant mitral regurgitation
   Predominant mitral stenosis
   Mixed steno-regurgitation
   Prosthetic valve failure
   123 (50.4)
     72 (29.5)
     45 (18.4)
     4 (1.6)
60 (62.5)
20 (20.8)
13 (13.5)
3 (3.1)
0.139
Echocardiographic data
   LV ejection fraction (%)
   LA dimension (mm)
   LV end systolic diameter (mm)
   LV end diastolic diameter (mm)
  55.0±10.1
60.9±9.5
40.4±8.5
58.3±9.7
  55.8±10.1
  60.5±10.6
40.2±8.7
58.5±9.9
0.468
0.735
0.812
0.808
AF profiles
   AF duration (yr)
   Fine (<1 mm) AF wave, n (%)
   AF type, n (%)
      Paroxysmal
      Persistent (<1 yr)
      Longstanding persistent (≥1 yr)
  5.7±6.8
   116 (47.5)
   20 (8.2)
     41 (16.8)
   183 (75.0)
  5.7±7.2
49 (51.0)
13 (13.5)
12 (12.5)
71 (74.0)
0.977
0.561
0.240
Data represent mean±SD. *P<0.05.
MV, mitral valve; LV, left ventricle; LA, left atrium; AF, atrial fibrillation. Kim JB, et al.  •   Microwave Ablation vs. Cryoablation for Surgical Treatment of Atrial Fibrillation
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multivariable models. Multivariate analyses involved a back-
ward elimination technique and only variables with a P value 
of <0.10 were used in the final model. Results were expressed as 
hazard ratios (HR) with 95% confidence intervals (CI). All report-
ed P values are two-sided, and P values of less than 0.05 were 
considered to indicate statistical significance. SAS software, ver-
sion 9.1 (SAS Institute, Cary, NC, USA) and SPSS version 12 were 
used for the statistical analysis.
  This study was approved by our institutional review board 
(IRB No. 2008-0638). The informed consent was waived by the 
board because of the retrospective nature of our study.
RESULTS
Mean age at the time of operation was 50.0±12.5 yr, and 208 (61.2 
%) patients were female. There were seven early deaths. Among 
the early survivors (n=333), follow-up EKG analysis beyond 12 
months postoperation was possible in 319 patients (95.8%); this 
analysis was not possible in 4 patients due to death within 12 
months and 10 patients who were lost to follow-up. The mean 
follow-up period was 46.1±28.2 months.
  Preoperative patient characteristics are listed in Table 1. Pa-
tients in the Cryo group were more likely to have rheumatic MV 
disease than those in the MW group, significantly. Otherwise, 
the two groups were similar in terms of preoperative patient 
demographic profiles, clinical features of mitral valve disease 
and AF, and preoperative echocardiographic data.
  The aortic clamping time was significant longer in the Cryo 
group than the MW group (Table 2). There were no significant 
between-group differences in other operative parameters includ-
ing duration of cardiopulmonary bypass, type of mitral valve pro-
cedure and concomitant cardiac procedure (Table 2). There were 
four cases of late stroke (1.2%) and seven late deaths (2.1%; Table 
3). Overall 3-yr and 5-yr survival rates were 96.1±1.1% and 95.6± 
1.2%, respectively. Three patients (0.9%) failed to regain normal 
sinus rhythm and nine patients (2.6%) required permanent pace-
maker implantation. The rates of sinus rhythm restoration and 
rhythm at last follow-up were similar for the two groups (Table 3). 
  Ninety patients (26.5%) experienced early AF events (58 in 
the Cryo group and 32 in the MW group, P=0.320). Sixty patients 
(17.6%) experienced late AF recurrence during the follow-up 
period (43 in the Cryo group and 17 in the MW group, P=0.755). 
All of these 60 patients with late AF recurrence received amiod-
arone medication, which resulted in sinus rhythm conversion in 
all patients. Of them, 32 experienced AF recurrence after discon-
tinuation of amiodarone medication, and subsequently restart-
ed the amiodarone medication. None of the patients who expe-
rienced late AF recurrence progressed to persistent AF. An ad-
ditional 21 patients had received amiodarone medication since 
the early postoperative period and 14 of these patients eventu-
ally discontinued amiodarone therapy without experiencing late 
AF recurrence. Other three patients had been receiving amiod-
arone at the time of analysis but without experiencing AF recur-
rence.
Table 2. Operative procedures
Operation types
Cryo group 
(n=244)
MW group 
(n=96)
P 
value
Cardiopulmonary bypass time (min) 163.7±50.4 164.7±36.4 0.850
Aorta cross clamping time (min) 119.5±34.0 109.2±28.6  0.005*
Type of mitral valve procedure, n (%)
   Repair
   Replacement
131 (53.7)
113 (46.3)
57 (59.4)
39 (40.6)
0.342
Concomitant tricuspid valve repair, n (%) 120 (49.2) 48 (50.0) 0.892
Other cardiac co-operation
   None
   Aortic valve surgery
   Coronary artery bypassing
   Others
 184 (75.4)
  39
† (16.0)
17
† (7.0)
   8 (3.3)
74 (77.1)
14 (14.6)
2 (2.1)
6 (6.3)
0.447
Data represent mean±SD.
*P<0.05; 
†Four patients underwent aortic valve surgery plus coronary artery bypassing. 
Table 3. Operative outcomes
Outcomes Cryo group MW group P value
Early mortality, n (%)   5 (2.0) 2 (2.1) >0.999
Late mortality, n (%)   5 (2.0) 2 (2.1) >0.999
Stroke, n (%)   3 (3.1) 1 (1.0) >0.999
Sinus conversion date, days 1.2±6.5 0.4±1.9   0.149
Recent follow up rhythm, n (%)
   Normal sinus rhythm
   Atrial fibrillation or flutter
   Junctional
   Pacemaker rhythm
210 (86.1)
17 (7.0)
  3 (1.2)
  7 (2.9)
79 (82.3)
9 (9.4)
3 (3.1)
2 (2.1)
  0.531
Data represent mean±SD. *P<0.05.
Fig. 1. Freedom from AF without administration of antiarrhythmic agents. In the Cryo 
group, the AF-free rates were 87.8%±2.2% at 3 yr and 79.9%±3.2% at 5 yr. In the 
MW group, the AF-free rates were 79.9%±4.9% at 3 yr and 61.3%±1.2% at 5 yr 
(P=0.089). 
AF, atrial fibrillation.
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  Overall unadjusted 3-yr, 5-yr and 7-yr AF-free rates in patients 
who did not receive antiarrhythmic agents were 85.9±2.1%, 78.1± 
2.9% and 70.2±4.4%, respectively. The MW group had a greater 
tendency of AF-recurrence rate than the Cryo group (Fig. 1). After 
adjustment for baseline patients’ characteristics with IPTW, the 
MW group only showed a tendency toward more frequent AF 
recurrence than the Cryo group (Hazard ration 1.66, 95% confi-
dence interval 0.89 to 3.07). Univariate and multivariate analy-
ses for a range of variables revealed that older patient age (P< 
0.001) and greater LA size (P<0.001) were independent factors 
for late AF recurrence (Table 4). 
  Transmitral A-wave prevalence and velocity plots are shown 
in Figs. 2, 3, respectively. There were no significant differences 
in transmitral A-wave prevalence and velocity between groups 
at each postoperative time point.
DISCUSSION
Alternative energy sources are being increasingly used in the 
field of AF ablation surgery owing to their convenience in appli-
cation, shorter procedural time and minimal risk of postopera-
tive bleeding. Endocardial ablations have demonstrated a 70–
80% long-term success rate when used together with other open 
heart procedures. Progress has focused on rapidly, efficiently, 
and safely creating therapeutic ablative lesions without incision. 
Delivery systems are designed to be precise, flexible and able to 
access any anatomic location. Owing to the development of these 
delivery systems, AF ablation surgery has evolved to become an 
endoscopic, off-pump, robotically assisted successful procedure 
for the treatment of AF (6).
  Cryoablation was the first alternative approach to be used in 
AF ablation surgery (15), and thus has the advantage that it is 
the most time-tested and has a well-characterized safety pro-
file. Several studies have reported long-term results of cryoab-
lation for treatment of AF and have shown that it has similar re-
sults as the conventional ‘cut and sew’ Cox Maze procedure in 
terms of restoration and maintenance of sinus rhythm (16-18).
  Microwave ablation has several advantages, in that, shielded 
probes enable a minimally invasive off-pump epicardial ap-
proach, potentially no cardiac ischemic time requirement, bet-
ter handling of anatomic variation, avoidance of a left atrioto-
my, and a less risk of pulmonary vein stenosis (19). It can accom-
modate a variety of lesion sets. However, in contrast to cryoab-
lation, most studies have recorded follow-up rhythm data after 
microwave ablation for less than 1 yr (6-9). Determining the clin-
ical effectiveness of AF ablation therapy based on 1 yr follow-up 
data seems inadequate, particularly because in 2007 the Heart 
Rhythm Society Task Force on Catheter and Surgical Ablation 
of AF recommended that all patients in a clinical investigation 
Fig. 2. Transmitral A-wave prevalence (%). Inter-group comparisons of A-wave preva-
lence show no differences during the postoperative period (P values ranged from 0.18 
to 1.0 for each postoperative point).
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Fig. 3. Transmitral peak A-wave velocity (cm/sec). Inter-group comparisons of A-wave 
velocity show no differences during the postoperative period (P values ranged from 
0.16 to 0.84 for each postoperative point).
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Table 4. Univariate and multivariate analyses for late atrial fibrillation recurrence
Variables
Univariate 
P value
Multivariate 
HR 95.0% C.I. P value
Age (yr) 0.004* 1.04 1.02–1.06 <0.001*
Diabetes mellitus 0.045*
Cardiothoracic ratio 0.018*
Left ventricular ejection fraction 0.166
Left atrial dimension <0.001* 1.06 1.03–1.08 <0.001*
AF duration 0.002*
Fine (<1 mm) AF wave 0.007*
AF type (paroxysmal vs persistent) 0.070
Concomitant tricuspid valvuloplasty 0.046*
Energy source (cryoablation vs.   
  microwave)
0.089*
*P<0.05.
AF, atrial fibrillation. Kim JB, et al.  •   Microwave Ablation vs. Cryoablation for Surgical Treatment of Atrial Fibrillation
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should be followed for a minimum of 12 months (10). To our 
knowledge, only one study has investigated the long-term (>1 
yr) outcomes of left atrial endocardial microwave ablation (20). 
In this previous study, 41 patients were enrolled and the mean 
duration of postoperative follow-up was 5.37±0.91 yr. After 5 yr, 
only 39.3% of patients were in sinus rhythm. The investigators 
concluded that microwave ablation is not a reliable method for 
achieving long-term conversion to sinus rhythm. Although the 
AF ablation procedure used in this previous study was not a bi-
atrial full maze procedure, the results were significant because 
they were the first reported data on the long-term outcomes of 
microwave ablation and because they were quite different from 
previous relatively short-term data indicating that the technique 
is excellent (7-9). The authors suggested that an important rea-
son for the modest conversion rate to sinus rhythm in their study 
was a lack of lesion transmurality.
  In support of their hypothesis, a postmortem histologic study 
was conducted in which three patients underwent microwave 
ablation for the treatment of AF (21). All three patients had im-
mediate successful sinus rhythm restoration, and autopsies per-
formed within 22 days of surgery showed that in most tissue sam-
ples, the lesions were not transmural and the extent of myocar-
dial damage was highly variable. 
  In the present study, the analyses showed a trend toward fa-
voring the use of cryoablation than the microwave ablation in 
terms of the restoration and maintenance of sinus rhythm dur-
ing a long-term follow-up. This difference in late outcomes has 
not been reported previously. Although histologic examinations 
of ablated atrial tissue were not performed in this study, we as-
sume the differences in long-term rhythm outcomes between 
microwave and cryoablation are due to differences in the ability 
to produce transmural necrosis, in agreement with a previous 
proposal (20). Application of a nitrous-oxide-based cryoabla-
tion probe at -60°C to atrial tissue for 2 min creates a transmural 
lesion that can be visually verified (22). However, the current 
microwave ablation approach lacks a transmural feedback mech-
anism, making it difficult to verify the transmural necrosis dur-
ing the procedure. 
  In the present study, the microwave energy level used was 65 
watts and the duration of ablation was 2 min per lesion; this level 
of energy delivery is above the level which has been suggested 
and used by other researchers. Tissue shrinking of lesion lines 
on endocardial surface with dark yellow discoloration could be 
observed following the procedure and this finding was regard-
ed as the indication of satisfactory injury in our practice. If the 
microwave energy is applied endocardially, most researchers 
use an energy power of 40 watts and an ablation time of 25 sec 
per lesion at a frequency of 2.45 GHz (9, 23). One research group 
(24) proposed 65 watts and 60 seconds of ablation time per le-
sion, and this energy level is also recommended by the device 
manufacturer for ‘epicardial’ application of microwave energy 
for beating-heart AF ablation (25). However, to investigate the 
long-term rhythm outcome, we suggest that the level of energy 
and the duration of ablation should be evaluated and determin-
ed according to the long-term rhythm status in the clinical set-
ting. Further investigations are needed to address this issue.
  In this study, the aortic clamping time was longer in the Cryo 
group than the MW group. When a microwave probe is applied, 
it takes about 2 min to create each linear lesion, whereas cryo-
ablation takes 2 min of freezing plus about 20 sec of warming. 
Furthermore, the flexible nature of microwave probes makes it 
easier to rapidly generate the lesions, so additional time can be 
saved.
  This study is subject to the limitations inherent to retrospec-
tive observational studies. Although the analyses showed a def-
inite trend toward favoring the use of cryoablation than the mi-
crowave ablation in terms of freedom from AF, the results were 
statistically marginal. Studies on a larger population or a longer 
follow-up duration are necessary to verify the current study re-
sults. 
  We could not identify the reason for the different AF recur-
rence rate seen with different energy sources. Documentation 
of online electrophysiologic evaluation during microwave abla-
tion may have given an indication of the device to create trans-
mural lesions acutely. 
  In conclusion, both the MW and Cryo groups show excellent 
early operative results, although the aortic clamping time is 
longer in the Cryo group compared with the MW group. Rates 
of atrial contractility restoration after surgery are similar in the 
two groups. However, patients who underwent microwave ab-
lation exhibit tendency toward more frequent AF recurrence 
than those who underwent cryoablation. We assume the differ-
ences in long-term rhythm outcomes between these two energy 
sources are due to the difference in the ability to produce trans-
mural necrosis. Further investigations involving histologic eval-
uations are needed to address this issue.
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